Oncolytics Biotech ONCY

$ 0.85 -3.92%

Annual report 2023
added 12-21-2024

Oncolytics Biotech Balance Sheet 2011-2024 | ONCY

Annual Balance Sheet Oncolytics Biotech

	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-	-	-	-13.7 M	-11.8 M	-12 M	-24 M	-14.2 M	-25.2 M	-19.3 M	-32.9 M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	133 K	216 K	294 K	249 K	340 K	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	6.88 M	6.9 M	5.86 M	4.64 M	-	-	-	-	-	-
Total Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	11.3 M	10.8 M	9.78 M	9.59 M	19.8 M	8.67 M	9.87 M	4.07 M	2.71 M	3.37 M	6.01 M	7.29 M	6.5 M
Deferred Revenue	-	-	-	-	-	927 K	1.55 M	-	-	-	-	-	-
Retained Earnings	-	-	-	-367 M	-345 M	-311 M	-294 M	-279 M	-264 M	-250 M	-231 M	-208 M	-171 M
Total Assets	38.8 M	37.3 M	45.9 M	34.3 M	19.7 M	14.9 M	18.2 M	14.8 M	27.4 M	17.2 M	28.2 M	22.1 M	36 M
Cash and Cash Equivalents	34.9 M	11.7 M	41.3 M	31.2 M	14.1 M	13.7 M	11.8 M	12 M	24 M	-	-	-	-
Book Value	27.6 M	26.5 M	36.1 M	24.8 M	-108 K	6.2 M	8.28 M	10.7 M	24.7 M	13.8 M	22.2 M	14.8 M	29.5 M
Total Shareholders Equity	-	-	-	24.8 M	-108 K	6.2 M	8.28 M	10.7 M	24.7 M	-	-	-	-

All numbers in CAD currency

Quarterly Balance Sheet Oncolytics Biotech

	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	-	-	-	361 K	-	-	-	153 K	-	-	-	166 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	6.88 M	-	-	-	6.9 M	-	-	-	5.86 M	-	-	-	4.64 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	-	-	-	-	9.78 M	-	-	-	9.59 M	-	-	-	19.8 M	-	-	-	8.67 M	-	-	-	9.87 M	-	-	-	4.07 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-	-	-	-	-393 M	-	-	-	-367 M	-	-	-	-345 M	-	-	-	-311 M	-	-	-	-294 M	-	-	-	-279 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	-	-	-	-	45.9 M	-	-	-	34.3 M	-	-	-	19.7 M	-	-	-	14.9 M	-	-	-	18.2 M	-	-	-	14.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	-	-	-	-	41.3 M	-	-	-	31.2 M	-	-	-	14.1 M	-	-	-	13.7 M	-	-	-	11.8 M	-	-	-	12 M	-	-	-	24 M	-	-	-	14.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	-	-	-	-	36.1 M	-	-	-	24.8 M	-	-	-	-108 K	-	-	-	6.2 M	-	-	-	8.28 M	-	-	-	10.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	-	-	-	-	36.1 M	-	-	-	24.8 M	-	-	-	-108 K	-	-	-	6.2 M	-	-	-	8.28 M	-	-	-	10.7 M	-	-	-	24.7 M	-	-	-	13.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in CAD currency